{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:23:17Z","timestamp":1791271397914,"version":"4.1.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T00:00:00Z","timestamp":1277769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/nrcardio.2010.101","type":"journal-article","created":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T09:28:49Z","timestamp":1277803729000},"page":"498-509","source":"Crossref","is-referenced-by-count":43,"title":["New antithrombotic agents\u2014insights from clinical trials"],"prefix":"10.1038","volume":"7","author":[{"given":"Jeremy S.","family":"Paikin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,29]]},"reference":[{"key":"BFnrcardio2010101_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nature06797","volume":"451","author":"N Mackman","year":"2008","unstructured":"Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914\u2013918 (2008).","journal-title":"Nature"},{"issue":"Suppl. 1","key":"BFnrcardio2010101_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1538-7836.2007.02499.x","volume":"5","author":"JW Eikelboom","year":"2007","unstructured":"Eikelboom, J. W. & Hirsh, J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J. Thromb. Hemost. 5 (Suppl. 1), 255\u2013263 (2007).","journal-title":"J. Thromb. Hemost."},{"key":"BFnrcardio2010101_CR3","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent, C. et al. for the Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849\u20131860 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio2010101_CR4","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono, C., Garc\u00eda Rodr\u00edguez, L. A., Landolfi, R. & Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353, 2373\u20132383 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1136\/bmj.328.7438.477","volume":"328","author":"GJ Hankey","year":"2004","unstructured":"Hankey, G. J. & Eikelboom, J. W. Aspirin resistance. BMJ 328, 477\u2013479 (2004).","journal-title":"BMJ"},{"key":"BFnrcardio2010101_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1055\/s-2005-869523","volume":"31","author":"P Savi","year":"2005","unstructured":"Savi, P. & Herbert, J. M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin. Thromb. Hemost. 31, 174\u2013183 (2005).","journal-title":"Semin. Thromb. Hemost."},{"key":"BFnrcardio2010101_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"ME Bertrand","year":"2000","unstructured":"Bertrand, M. E., Rupprecht, H. J., Urban, P., Gershlick, A. H. for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102, 624\u2013629 (2000).","journal-title":"Circulation"},{"key":"BFnrcardio2010101_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf, S. et al. for the CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494\u2013502 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine, M. S. et al. for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352, 1179\u20131189 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR10","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen, Z. M. et al. for the COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607\u20131621 (2005).","journal-title":"Lancet"},{"key":"BFnrcardio2010101_CR11","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1053\/euhj.2000.2474","volume":"21","author":"SR Mehta","year":"2000","unstructured":"Mehta, S. R. & Yusuf, S. for the CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial program; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur. Heart J. 21, 2033\u20132041 (2000).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2010101_CR12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","volume":"294","author":"MS Sabatine","year":"2005","unstructured":"Sabatine, M. S. et al. for the CLARITY-TIMI 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294, 1224\u20131232 (2005).","journal-title":"JAMA"},{"key":"BFnrcardio2010101_CR13","first-page":"e148","volume":"116","author":"JL Anderson","year":"2007","unstructured":"Anderson, J. L. et al. ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116, e148\u2013e304 (2007).","journal-title":"Circulation"},{"key":"BFnrcardio2010101_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.107.188208","volume":"117","author":"SB King 3rd","year":"2008","unstructured":"King, S. B. 3rd et al. 2007 Focused Update of the ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117, 261\u2013295 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio2010101_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1160\/TH09-08-0580","volume":"103","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y. et al. for the European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting. Thromb. Hemost. 103, 13\u201328 (2010).","journal-title":"Thromb. Hemost."},{"key":"BFnrcardio2010101_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/ncpcardio1372","volume":"5","author":"NC Raju","year":"2008","unstructured":"Raju, N. C., Eikelboom, J. W. & Hirsh, J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat. Clin. Pract. Cardiovasc. Med. 5, 766\u2013780 (2008).","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"BFnrcardio2010101_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jacc.2008.01.051","volume":"51","author":"JA Cairns","year":"2008","unstructured":"Cairns, J. A. & Eikelboom, J. Clopidogrel resistance: more grist for the mill. J. Am. Coll. Cardiol. 51, 1935\u20131937 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2010101_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega, J. L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354\u2013362 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon, T. et al. for the FAST-MI Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363\u2013375 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR20","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","volume":"51","author":"D Trenk","year":"2008","unstructured":"Trenk, D. et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol. 51, 1925\u20131934 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2010101_CR21","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","volume":"4","author":"M Gilard","year":"2006","unstructured":"Gilard, M., Arnaud, B., Le Gal, G., Abgrall, J. F. & Boschat, J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Hemost. 4, 2508\u20132509 (2006).","journal-title":"J. Thromb. Hemost."},{"key":"BFnrcardio2010101_CR22","doi-asserted-by":"publisher","first-page":"148.e1","DOI":"10.1016\/j.ahj.2008.09.017","volume":"157","author":"JM Siller-Matula","year":"2009","unstructured":"Siller-Matula, J. M. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157, 148.e1\u2013148.e5 (2009).","journal-title":"Am. Heart J."},{"key":"BFnrcardio2010101_CR23","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.109.907295","volume":"120","author":"DN Juurlink","year":"2009","unstructured":"Juurlink, D. N. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 120, 2310\u20132312 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio2010101_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","volume":"374","author":"ML O'Donoghue","year":"2009","unstructured":"O'Donoghue, M. L. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374, 989\u2013997 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio2010101_CR25","unstructured":"Mehta, S. R. & Van de Werf, F. A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial. Presented at the European Society of Cardiology Congress 2009."},{"key":"BFnrcardio2010101_CR26","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJM199106273242606","volume":"324","author":"J Hirsh","year":"1991","unstructured":"Hirsh, J. Oral anticoagulant drugs. N. Engl. J. Med. 324, 1865\u20131875 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1124\/dmd.106.014522","volume":"35","author":"NA Farid","year":"2007","unstructured":"Farid, N. A. et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos. 35, 1096\u20131104 (2007).","journal-title":"Drug Metab. Dispos."},{"key":"BFnrcardio2010101_CR28","doi-asserted-by":"publisher","first-page":"66.e9","DOI":"10.1016\/j.ahj.2006.10.010","volume":"153","author":"JT Brandt","year":"2007","unstructured":"Brandt, J. T. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153, 66.e9\u201366.e16 (2007).","journal-title":"Am. Heart J."},{"key":"BFnrcardio2010101_CR29","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","volume":"27","author":"T Jernberg","year":"2006","unstructured":"Jernberg, T. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27, 1166\u20131173 (2006).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2010101_CR30","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","volume":"5","author":"JT Brandt","year":"2007","unstructured":"Brandt, J. T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Hemost. 5, 2429\u20132436 (2007).","journal-title":"J. Thromb. Hemost."},{"key":"BFnrcardio2010101_CR31","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","volume":"119","author":"JL Mega","year":"2009","unstructured":"Mega, J. L. et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553\u20132560 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio2010101_CR32","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D. et al. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001\u20132015 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR33","unstructured":"A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS). ClinicalTrials.gov identifier: NCT00699998 [online] , (2010)."},{"key":"BFnrcardio2010101_CR34","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S Husted","year":"2006","unstructured":"Husted, S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27, 1038\u20131047 (2006).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2010101_CR35","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","volume":"50","author":"RF Storey","year":"2007","unstructured":"Storey, R. F. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50, 1852\u20131856 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2010101_CR36","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel, P. A. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation 120, 2577\u20132585 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio2010101_CR37","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","volume":"121","author":"PA Gurbel","year":"2010","unstructured":"Gurbel, P. A. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121, 1188\u20131199 (2010).","journal-title":"Circulation"},{"key":"BFnrcardio2010101_CR38","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. et al. for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045\u20131057 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR39","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/eurheartj\/ehp545","volume":"31","author":"VL Serebruany","year":"2010","unstructured":"Serebruany, V. L. & Atar, D. The PLATO trial: do you believe in magic? Eur. Heart J. 31, 764\u2013767 (2010).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2010101_CR40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1055\/s-0037-1615596","volume":"85","author":"RF Storey","year":"2001","unstructured":"Storey, R. F., Oldroyd, K. G. & Wilcox, R. G. Open multicenter study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Hemost. 85, 401\u2013407 (2001).","journal-title":"Thromb. Hemost."},{"key":"BFnrcardio2010101_CR41","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington, R. A. et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361, 2318\u20132329 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR42","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt, D. L. et al. for the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361, 2330\u20132341 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR43","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMe0910677","volume":"361","author":"A Kastrati","year":"2009","unstructured":"Kastrati, A. & Ndrepepa, G. Cangrelor\u2014a champion lost in translation? N. Engl. J. Med. 361, 2382\u20132384 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR44","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","volume":"121","author":"SR Steinhubl","year":"2008","unstructured":"Steinhubl, S. R. et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res. 121, 527\u2013534 (2008).","journal-title":"Thromb. Res."},{"key":"BFnrcardio2010101_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1160\/TH09-07-0434","volume":"103","author":"JI Weitz","year":"2010","unstructured":"Weitz, J. I. New oral anticoagulants in development. Thromb. Hemost. 103, 62\u201370 (2010).","journal-title":"Thromb. Hemost."},{"key":"BFnrcardio2010101_CR46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1160\/TH06-05-0234","volume":"96","author":"JI Weitz","year":"2006","unstructured":"Weitz, J. I. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb. Hemost. 96, 274\u2013284 (2006).","journal-title":"Thromb. Hemost."},{"key":"BFnrcardio2010101_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","volume":"48","author":"BI Eriksson","year":"2009","unstructured":"Eriksson, B. I., Quinlan, D. J. & Weitz, J. I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin. Pharmacokinet. 48, 1\u201322 (2009).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrcardio2010101_CR48","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1160\/TH06-05-0234","volume":"96","author":"JI Weitz","year":"2006","unstructured":"Weitz, J. I. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb. Hemost. 96, 274\u2013284 (2006).","journal-title":"Thromb. Hemost."},{"key":"BFnrcardio2010101_CR49","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly, S. J. et al. for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139\u20131151 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR50","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","volume":"27","author":"F Andreotti","year":"2006","unstructured":"Andreotti, F., Testa, L., Biondi-Zoccai, G. G. & Crea, F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur. Heart J. 27, 519\u2013526 (2006).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2010101_CR51","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857\u2013867 (2007).","journal-title":"Ann. Intern. Med."},{"key":"BFnrcardio2010101_CR52","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson, B. I. et al. for the RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Hemost. 5, 2178\u20132185 (2007).","journal-title":"J. Thromb. Hemost."},{"key":"BFnrcardio2010101_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0883-5403(08)00834-6","volume":"24","author":"JS Ginsberg","year":"2009","unstructured":"Ginsberg, J. S. et al. for the RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 24, 1\u20139 (2009).","journal-title":"J. Arthroplasty"},{"key":"BFnrcardio2010101_CR54","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"BI Eriksson","year":"2007","unstructured":"Eriksson, B. I. et al. for the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370, 949\u2013956 (2007).","journal-title":"Lancet"},{"key":"BFnrcardio2010101_CR55","unstructured":"Dabigatran etexilate compared with enoxaparin in prevention of VTE following total hip arthroplasty. ClinicalTrials.gov identifier: NCT00657150 [online] , (2010)."},{"key":"BFnrcardio2010101_CR56","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman, S. et al. for the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342\u20132352 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR57","unstructured":"RE-DEEM dose finding study for dabigatran etexilate in patients with acute coronary syndrome.ClinicalTrials.gov identifier: NCT00621855 [online] , (2010)."},{"key":"BFnrcardio2010101_CR58","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen, M. R. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361, 594\u2013604 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR59","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","volume":"375","author":"MR Lassen","year":"2010","unstructured":"Lassen, M. R. et al. for the ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375, 807\u2013815 (2010).","journal-title":"Lancet"},{"key":"BFnrcardio2010101_CR60","unstructured":"Study of an investigational drug for the prevention of thrombosis-related events following hip replacement surgery. ClinicalTrials.gov identifier: NCT00423319 [online] , (2010)."},{"key":"BFnrcardio2010101_CR61","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Alexander, J. H. et al. for the APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119, 2877\u20132885 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio2010101_CR62","unstructured":"Phase III acute coronary syndrome (APPRAISE-2). ClinicalTrials.gov identifier: NCT00831441 [online] , (2010)."},{"key":"BFnrcardio2010101_CR63","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson, B. I. et al. for the RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765\u20132775 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar, A. K. et al. for the RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372, 31\u201339 (2008).","journal-title":"Lancet"},{"key":"BFnrcardio2010101_CR65","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen, M. R. et al. for the RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776\u20132786 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2010101_CR66","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie, A. G. et al. for the RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373, 1673\u20131680 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio2010101_CR67","doi-asserted-by":"crossref","unstructured":"Buller, H. R. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The EINSTEIN-Extension Study. Presented at the 51st American Society of Hematology Meeting 2009.","DOI":"10.1182\/blood.V114.22.LBA-2.LBA-2"},{"key":"BFnrcardio2010101_CR68","unstructured":"Bayer AG. Phase III EINSTEIN-Extension study of Bayer's rivaroxaban shows significant benefit in the prevention of secondary symptomatic VTE Bayer: Science for Better Life [online] , (2010)."},{"key":"BFnrcardio2010101_CR69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega, J. L. et al. for the ATLAS ACS\u2013TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS\u2013TIMI 46): a randomised, double-blind, phase II trial. Lancet 374, 29\u201338 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio2010101_CR70","unstructured":"An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. ClinicalTrials.gov identifier: NCT00809965 [online] , (2010)."},{"key":"BFnrcardio2010101_CR71","unstructured":"Dabigatran etexilate compared with enoxaparin in prevention of VTE following total hip arthroplasty. ClinicalTrials.gov identifier: NCT00657150 [online] , (2010)."},{"key":"BFnrcardio2010101_CR72","unstructured":"Phase III study testing efficacy and safety of oral dabigatran etexilate versus warfarin for 6\u00a0month treatment of acute symptomatic VTE. ClinicalTrials.gov identifier: NCT00680186 [online] , (2010)."},{"key":"BFnrcardio2010101_CR73","unstructured":"Secondary prevention of venous thromboembolism. ClinicalTrials.gov identifier: NCT00329238 [online] , (2010)."},{"key":"BFnrcardio2010101_CR74","unstructured":"Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic VTE. ClinicalTrials.gov identifier: NCT00558259 [online] , (2010)."},{"key":"BFnrcardio2010101_CR75","unstructured":"Study of apixaban for the prevention of thrombosis-related events in patients with acute medical illness (ADOPT). ClinicalTrials.gov identifier: NCT00457002 [online] , (2010)."},{"key":"BFnrcardio2010101_CR76","unstructured":"Efficacy and safety study of apixaban in the treatment of deep vein thrombosis or pulmonary embolism. ClinicalTrials.gov identifier: NCT00643201 [online] , (2010)."},{"key":"BFnrcardio2010101_CR77","unstructured":"Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. ClinicalTrials.gov identifier: NCT00633893 [online] , (2010)."},{"key":"BFnrcardio2010101_CR78","unstructured":"A phase III study of apixaban in patients with atrial fibrillation (AVERROES). ClinicalTrials.gov identifier: NCT00496769 [online] , (2010)."},{"key":"BFnrcardio2010101_CR79","unstructured":"Apixaban for the prevention of stroke in subjects with atrial fibrillation (ARISTOTLE). ClinicalTrials.gov identifier: NCT00412984 [online] , (2010)."},{"key":"BFnrcardio2010101_CR80","unstructured":"Venous Thromboembolic event (VTE) prophylaxis in medically ill patients (MAGELLAN). ClinicalTrials.gov identifier: NCT00571649 [online] , (2010)."},{"key":"BFnrcardio2010101_CR81","unstructured":"Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis without pulmonary embolism: Einstein-DVT evaluation. ClinicalTrials.gov identifier: NCT00440193 [online] , (2010)."},{"key":"BFnrcardio2010101_CR82","unstructured":"Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. ClinicalTrials.gov identifier: NCT00439777 [online] , (2010)."},{"key":"BFnrcardio2010101_CR83","unstructured":"An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. ClinicalTrials.gov identifier: NCT00809965 [online] , (2010)."},{"key":"BFnrcardio2010101_CR84","unstructured":"Efficacy and safety of rivaroxaban for the prevention of stroke in subjects with non-valvular atrial fibrillation. ClinicalTrials.gov identifier: NCT00494871 [online] , (2010)."},{"key":"BFnrcardio2010101_CR85","unstructured":"Randomized, double-blind study comparing once-daily oral rivaroxaban with adjusted-dose oral warfarin for the prevention of stroke in subjects with non-valvular atrial fibrillation. ClinicalTrials.gov identifier: NCT00403767 [online] , (2010)."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2010.101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2010.101","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2010.101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:45:09Z","timestamp":1684467909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2010.101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,29]]},"references-count":85,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFnrcardio2010101"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2010.101","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,29]]}}}